Κατάλογος ενδεικτικών δημοσιεύσεων του τμήματος Ιατρικής ΑΠΘ σε διεθνή επιστημονικά περιοδικά κατά τα τελευταία 5 έτη.
GLP-1 receptor agonists and SGLT2 inhibitors for older people with type 2 diabetes: A systematic review and meta-analysis..
Diabetes Res Clin Pract. 174, 108737.
(2021). Medical treatment as an alternative to adrenalectomy in patients with aldosterone-producing adenomas..
Endocr Relat Cancer. 15(3), 693-700.
(2008). Lack of an association between angiotensin-converting enzyme gene insertion/deletion polymorphism and ischaemic stroke..
Eur Neurol. 51(3), 148-52.
(2004). Canagliflozin in the treatment of type 2 diabetes: an evidence-based review of its place in therapy..
Core Evid. 12, 1-10.
(2017). Eplerenone relieves spironolactone-induced painful gynaecomastia in a patient with primary aldosteronism..
Nephrol Dial Transplant. 22(1), 293.
(2007). Atherosclerotic renal artery stenosis: medical therapy alone or in combination with revascularization?.
Angiology. 60(4), 397-402.
(2009). Plasma B-type natriuretic peptide is related to left ventricular mass in hypertensive patients..
Eur Heart J. 25(21), 1967.
(2004). Cardiovascular risk with DPP-4 inhibitors: latest evidence and clinical implications.
Therapeutic Advances in Drug Safety. 7(2), 36 - 38.
(2016). Seasonal variation in the occurrence of stroke in Northern Greece: a 10 year study in 8204 patients..
Neurol Res. 32(3), 326-31.
(2010). On the Origin of Dolabriferol: Total Synthesis via Its Putative Contiguous Precursor..
Org Lett. 18(15), 3794-7.
(2016). Gestational diabetes mellitus: why screen and how to diagnose..
Hippokratia. 14(3), 151-4.
(2010). The role of renin-angiotensin system inhibition in the treatment of hypertension in metabolic syndrome: are all the angiotensin receptor blockers equal?.
Expert Opin Ther Targets. 11(2), 191-205.
(2007). Serum uric acid as an independent predictor of early death after acute stroke..
Circ J. 71(7), 1120-7.
(2007). Gonadal dysfunction in systemic diseases..
Eur J Endocrinol. 152(4), 501-13.
(2005). Canagliflozin in the treatment of type 2 diabetes: an evidence-based review of its place in therapy.
Core Evidence. Volume 12, 1 - 10.
(2017). Pheochromocytoma: an update on genetics and management..
Endocr Relat Cancer. 14(4), 935-56.
(2007). Safety of dipeptidyl peptidase 4 inhibitors: a perspective review..
Ther Adv Drug Saf. 5(3), 138-46.
(2014). Effect of antihypertensive drug-associated diabetes on cardiovascular risk..
Hellenic J Cardiol. 51(3), 195-9.
(2010). A Methodological Framework for Meta-analysis and Clinical Interpretation of Subgroup Data: The Case of Major Adverse Cardiovascular Events With GLP-1 Receptor Agonists and SGLT2 Inhibitors in Type 2 Diabetes..
Diabetes Care. 47(2), 184-192.
(2024). Epidemiologic study of urolithiasis in seven countries of South-Eastern Europe: S.E.G.U.R. 1 study..
Arch Ital Urol Androl. 89(3), 173-177.
(2017). Cardiovascular risk with DPP-4 inhibitors: latest evidence and clinical implications..
Ther Adv Drug Saf. 7(2), 36-8.
(2016). Efficacy and safety of once-weekly glucagon-like peptide 1 receptor agonists for the management of type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials..
Diabetes Obes Metab. 17(11), 1065-74.
(2015). Paralysis as first manifestation of primary aldosteronism..
Nephrol Dial Transplant. 19(9), 2418-9.
(2004). Screening for coeliac disease in preschool Greek children: the feasibility study of a community-based project..
Acta Paediatr. 102(7), 749-54.
(2013).
(2011).